Karl Erik Hellström
Nessuna posizione attualmente
Profilo
Dr. Hellström received his M.D.
and Ph.D.
degrees from Karolinska Institute in Stockholm, Sweden, initially working in the area of tumor biology with an emphasis on immunogenetics.
As a student of George Klein, he was a member of the team that showed, for the first time, a tumor-destructive immune response to an animal's own autologous tumor.
After being recruited to the faculty of the University of Washington Medical School in 1966, Karl Erik Hellström and his wife, Dr. Ingegerd Hellström became internationally known after they reported that there is a T-lymphocyte-mediated immune response to human tumors, a discovery that opened new avenues for research and development of cancer therapy.
Precedenti posizioni note di Karl Erik Hellström
Società | Posizione | Fine |
---|---|---|
MARKER THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 05/12/2005 |
SEAGEN INC. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
MARKER THERAPEUTICS, INC. | Health Technology |
Aziende private | 1 |
---|---|
Seagen Inc.
Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
- Borsa valori
- Insiders
- Karl Erik Hellström